Opens in a new tab

NexCAR19™ Prescribing Information

HIGHLIGHTS OF PRESCRIBING INFORMATION

NexCAR19™ (Talicabtagene autoleucel) suspension for intravenous infusion
Generic Name:Autologous HCAR19 (2nd generation Anti-CD19-41BBCD3ζ chimeric antigen receptor T-cell therapy)
Nonproprietary Names (INN):Talicabtagene autoleucel (formerly known as Actalycabtagene autoleucel)
CDSCO approval:2023
CDSCO permission number:MF-01/2023

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES AND SECONDARY MALIGNANCIES

See full prescribing information for complete boxed warning.

  • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, can occur in patients receiving NexCAR19. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids (6.1).
  • Neurologic toxicities, including fatal or life-threatening reactions, can occur in patients receiving NexCAR19™, including concurrently with CRS or after CRS resolution. Patients must be monitored closely for symptoms that indicate onset of neurologic toxicities after treatment with NexCAR19™. Provide supportive care and/or corticosteroids as needed (6.2).
  • Patient with active neurological autoimmune or inflammatory disorder should be given NexCAR19™ at physician's discretion.
  • No T-cell malignancies have been reported in patients receiving NexCAR19™. T-cell malignancies have been reported with other BCMA and CD19 directed CAR-T cell therapies

INDICATIONS AND USAGE

NexCAR19™ is a 2nd generation Anti-CD19-4-1BB-CD3ζ chimeric antigen receptor T-cell therapy indicated for the treatment of patients (Age ≥ 15 years) diagnosed with -

  • Relapsed/ Refractory B-Cell Lymphomas (1).
  • Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (1).

Limitations of Use:

  • NexCAR19™ is not recommended for the treatment of patients with primary central nervous system lymphoma.
  • NexCAR19™ is not indicated for the treatment of patients with active CNS involvement by malignancy. Patients with a history of CNS disease that has been treated effectively will be eligible.
  • NexCAR19™ is not recommended for pregnant or lactating women. Pregnancy after treatment with NexCAR19™ infusion must be discussed with the treating physician.
  • NexCAR19™ is not recommended for the treatment of patients with active HIV or Hepatitis infections.

DOSAGE AND ADMINISTRATION

For autologous use only. For intravenous use only.

  • Do NOT use a leukoreduction filter.
  • Administer a lymphodepleting regimen of cyclophosphamide and fludarabine or bendamustine before infusion of NexCAR19™ (2.3.1).
  • Confirm Patient ID prior to infusion and verify Patient ID in a conspicuous manner.
  • Premedicate with acetaminophen and antihistamine prior to infusion (2.3.3).
  • Confirm availability of tocilizumab and anakinra prior to infusion (2.3.3).
  • The NexCAR19™ dose: ≥ 5 million CAR-T cells/ kg upto 2 x 109 viable CAR-T cells in a single infusion (2).

DOSAGE FORMS AND STRENGTHS

  • NexCAR19™ is available as a cell suspension for infusion (4).
  • Dosage Form: Cryopreserved viable CAR-T cells in infusion bag for single dose intravenous infusion(autologous) in 100 ml (4)
  • Composition: Each 100ml of cryopreserved cell suspension contains – 1 x 108 – 2 x 109 anti-CD 19 CAR-T cells, 5% Dimethyl sulfoxide (DMSO), 6% pentastarch, 3.4% human serum albumin (HSA) and 1000 IU Heparin in Plasma-Lyte A solution q.s(4)
  • Dose: ≥ 5 million CAR-T cells/ kg up to 2 x 109 viable CAR-T cells in a single infusion (4).

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

  • Aseptic Conditions: Proper Aseptic conditions should be followed while thawing and handling the product (14.2).
  • ICU support should be available at the clinical site where infusion is given (2.3.3).
  • Patients with active neurological autoimmune or inflammatory disorder should be given NexCAR19™ at physician's discretion (6.2).
  • Serious Infections: Monitor patients for signs and symptoms of infection; treat appropriately (6.4).
  • Prolonged Cytopenia: Patients may exhibit Grade 3 or higher cytopenia for several weeks following NexCAR19™ infusion. Monitor complete blood counts and manage as per institutional guidelines (6.5).
  • Hypogammaglobulinemia: Monitor and provide replacement therapy (6.6).
  • Effects on Ability to Drive and Use Machines: Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, for at least 8 weeks after receiving NexCAR19™ (6.11).
  • Do not thaw until the patient is ready for infusion. Once thawed, do not refreeze. (2.3.3)
  • To be provided on the prescription of a specialist/medical oncologist for the treatment of stated indication under this permission. (2.2)

ADVERSE REACTIONS

The most common adverse reactions excluding laboratory abnormalities, in patients with r/r B-cell Malignancies are Cytokine Release Syndrome (CRS), Hypogammaglobulinemia, Febrile reactions, fever, nausea, fatigue, Hemophagocytic lymphohistiocytosis (IEC-HS), ICAHT, Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and hypotension (7).

The most common Grade 3-4 laboratory abnormalities are neutropenia, anemia, thrombocytopenia, leukopenia, and lymphopenia (7).

See PATIENT COUNSELING INFORMATION and Medication Guide for more information (15)

FULL PRESCRIBING INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES

  • Cytokine Release Syndrome (CRS) occurred in patients receiving NexCAR19™. Do not administer NexCAR19™ to patients with active infections or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see Management of Severe Adverse Reactions (3), Warnings and Precautions].
  • Neurologic toxicities were not observed in patients receiving NexCAR19™. Monitor for neurologic toxicities after treatment with NexCAR19™. Provide supportive care and/or corticosteroids as needed [see Management of Severe Adverse Reactions (3), Warnings and Precautions].

1. INDICATIONS

Indications for NexCAR19™:

NexCAR19™ is a 2nd generation Anti-CD19-4-1BB-CD3ζ chimeric antigen receptor T-cell therapy indicated for the treatment of patients (Age ≥ 15 years) diagnosed with -

  • Relapsed/ Refractory B Cell Lymphomas
  • Relapsed/ Refractory B- Acute Lymphoblastic Leukemia

2. DOSAGE AND ADMINISTRATION

For autologous use only. For intravenous use only.

2.1. Dosage Form

Cryopreserved viable CAR-T cells in an infusion bag for single dose intravenous infusion (autologous) in 100 ml.

Composition: Each 100 ml of cryopreserved cell suspension contains –
1 x 108 – 2 x 109 anti-CD 19 CAR-T cells, 5% Dimethyl sulfoxide (DMSO), 6% pentastarch, 3.4% human serum albumin (HSA) and 1000 IU Heparin in Plasma-Lyte A solution q.s
Dose: ≥ 5 million CAR-T cells/ kg up to 2 x 109 viable CAR-T cells in a single infusion.

2.2. Administration

NexCAR19™ is to be provided on the prescription of a specialist/medical oncologist for the treatment of stated indication under this permission. NexCAR19™ is for autologous use only. The patient's identity must match the patient identifiers on the NexCAR19™ aluminum cassette and infusion bag. Confirm patient ID prior to infusion and verify patient ID in a conspicuous manner. Do not infuse NexCAR19™ if the information on the label does not match the intended patient.

Preparing Patient for NexCAR19™ Infusion

Confirm availability of NexCAR19™ prior to starting the lymphodepleting regimen.

2.3. Treatment Regimen
2.3.1 Lymphodepleting chemotherapy

A lymphodepleting chemotherapy has to be administered prior to the infusion of NexCAR19™. The following regimen is recommended to be used over three days:

Fludarabine 30 mg/m2 and Cyclophosphamide 500 mg/m2 for three days or Bendamustine 90 mg/m2 for 2 days for lymphoma patients with creatinine clearance of >/= 30 cc/min. Infusion is recommended to be given 2-7 days after lymphodepleting chemotherapy.

2.3.2 Infusion of NexCAR19™.

Dose: ≥ 5 million CAR-T cells/ kg up to 2 x 109 viable CAR-T cells in a single infusion.
Route of Administration: Single Dose Intravenous Infusion.

2.3.3 Preparation of NexCAR19™ for Infusion
  • Delay the infusion of NexCAR19™ if a patient has unresolved serious adverse reactions (including pulmonary reactions, cardiac reactions, or hypotension) from preceding chemotherapies, active uncontrolled infection, active graft versus host disease (GVHD), or worsening of leukaemia or lymphoma burden following lymphodepleting chemotherapy.
  • Verify the number of bag(s)s received for the dose of NexCAR19™ with the Product Information Sheet and Certificate of Analysis (CoA).
  • The product should not be infused if there is any visible damage or leakage in the bag(s). Inspect the bag(s) for the same. In case of any damage or leakage, do not infuse the patient; contact ImmunoACT.
  • Thawing process: The product should be gently thawed in a water bath at 36 to 38˚C. There should be no frozen clumps in the bag(s). The time between product thawing and completion of the infusion should not exceed 30 minutes to maintain maximum product viability. NexCAR19™ must not be thawed until the patient is ready for the infusion.
  • Pre-medication: Premedicate the patient with Inj. Avil 1 amp + Tab. Paracetamol 15mg/kg approximately 20 – 30 minutes prior to the infusion. Prior to NexCAR19™ infusion preparation, confirm the patient's identity with patient identifiers mentioned on the infusion bag(s). Confirm patient ID prior to infusion and verify patient ID in a conspicuous manner.
  • Monitoring:
    • Monitor patients following infusion for signs and symptoms of CRS and neurologic toxicities.
    • ICU support should be available at the clinical site where infusion is given.
    • Instruct patients to remain within proximity of the certified healthcare facility for at least 4 weeks following infusion.
    • Ensure that medications (tocilizumab/anakinra) required for the management of adverse events related to NexCAR19™ is available.
2.3.4 Incompatibilities

Following is the list of medications or therapies that are recommended to be kept on hold prior to apheresis and/or infusion:

  • Steroids must be stopped at least 24 hrs prior to apheresis and infusion.
  • Immunosuppressive medications and anti-proliferating therapies must be stopped at least 1 week prior to apheresis and infusion.
  • Short acting drugs like TKIs and hydroxyurea must be stopped at least 24 hrs prior to apheresis and infusion.
  • Cytotoxic drugs including low dose daily or weekly maintenance therapies must be stopped 1 week prior to apheresis and infusion
  • Antibodies including anti CD20 therapy must be stopped within 4 weeks before infusion or 5 half-lives respectively whichever is longer.
  • CNS disease prophylaxis must be stopped at least 1 week before infusion.
  • Radiation therapy should be stopped at least 1 week before infusion.
  • For leukemia patients, a time gap of at least 28 days must be maintained between donor lymphocyte infusions and NexCAR19™ infusions.
  • The patient who is post allogeneic stem-cell transplant should be off-immunosuppression for at least 2 weeks.

3. MANAGEMENT OF SEVERE ADVERSE REACTIONS

3.1. Cytokine Release Syndrome

Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. If CRS is suspected, manage according to ASTCT guidelines (Table 1).

Patients who experience Grade 2 or higher CRS (e.g., hypotension not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored. For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function. For severe or life- threatening CRS, consider intensive-care supportive therapy.

Table 1. CRS Management Guidance

S. NoCheckAction
1FeverInitiate Febrile Neutropenia management
Cardiac/SPO2 monitoring
Move to next step
2Blood pressure and SPO2 NormalSymptomatic treatment
Tocilizumab-1 dose if fever >3 days
3Hypotension and/or HypoxiaIVF 1-2-unit NS, repeat once
Supplemental oxygen, if needed.
Tocilizumab1 and
Dexamethosone 4-10 mg IV-1 dose
4Hypotension persists after IV fluids
Oxygen requirement > 6 l/min
2 D Echo, Cardiac markers
Start Vasopressors
Shift to ICU
Tocilizumab1
Dexamethasone -10mg-20mg2 q6h
Check Coagulopathy chart
5Hypotension persists-

> 1 Vasopressor (Exclude Vasopressin)
OR
Norepinephrine equivalent3 > 15 mcg/min

Positive pressure required NIV or mechanical ventilation
Tocilizumab1
Methylprednisolone 1g/day- 3 days
Refractory >24hrs or worsening
rapidly- Additional therapies4
Check coagulopathy chart

1Tocilizumab- 8mg/kg IV (Max dose-800mg), repeat upto 3 doses in 24 hrs, Maximum-4 doses for the entire course of CRS.

2 Dexamethasone- 10mg- 1 vasopressor, 20mg- 2 vasopressors/No improvement in hypoxia within 24 hours/progression of lung infiltrates/increase in FiO2

3 Norepinephrine equivalent dose = [norepinephrine (mcg/minute)] + [dopamine (mcg/kg/minute) / 2] + [epinephrine (mcg/minute)] + [phenylephrine (mcg/minute) / 10]

4Additional therapies-
1. Anakinra- 100 mg SC daily for 7 days (Avoid if Cr Clearance <30)
2. Cyclophosphamide- 1.5 g/m2 One dose (With Mesna 1.5g/m2 over 24 hours)
3. ATG- 1-2 mg/kg/d for D1-3, Premed with steroid and pheniramine, Infuse over 6h.

References: - 1. MDACC CARTOX guidelines 2018. 2. ASTCT classification BBMT 3. How I manage CAR-T toxicities Reagan P, JCO 2021.

3.2. Neurological Toxicity

Monitor patients for signs and symptoms of neurological toxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) (Table 2). Provide intensive-care supportive therapy for severe or life-threatening neurologic toxicities.

Table 2. Neurological Toxicity/ICANS Grading and Management Guidance

ICANS is defined by the presence of these symptoms in < 8 weeks from CAR-T infusion.
(IC bleed/tremors/myoclonus are not considered)

S. NoCheckAction
1IEC score1 7-9 AND
Wakes spontaneously
Evaluate for ICANS2
Supportive care3 (For all patients)
Dexamethasone 10 mg IV 1 dose and
reassess in 6 hours
2IEC score 3-6 OR
Awakes to verbal stimulus
Dexamethasone 10 mg IV q 12 hrs
Taper and stop once improvement
3IEC score 0-2 OR
Awakes to tactile stimulus OR
Any clinical seizure that resolves in <5min OR
Non-convulsive seizure that responds
to intervention Focal edema on imaging
Shift to ICU
Airway protection
If brain edema- Maintain MAP within 20-25 mm Hg of baseline MAP
Correct coagulopathy and uremia
Seizure management4
Monitor for ICT
Dexamethasone 10mg q6h, increase to 20mg q6h if Grade 3 persists 24h
Methylprednisolone 1g/d for 3 days and
taper-Focal edema in brainstem/thalamus.
4IEC score 0 OR
Requires deep stimulus/Stupor/Coma OR
Prolonged seizure > 5 min OR
Non-convulsive seizures that do not revert OR
Motor weakness OR
Diffuse cerebral edema/Increased ICT
Mechanical ventilation
Methylprednisolone 1g/d for 3 days followed by Taper.
Continue steroids till grade 1
Refractory >24h- Additional therapies5
5TocilizumabUse if concurrent CRS present

1 IEC score-

  • Orientation: Orientation to year, month, city, hospital: 4 points (1 point each)
  • Naming: Name 3 objects (e.g., clock, pen, button): 3 points (1 point each)
  • Following commands:(e.g., Show me 2 fingers or close your eyes and stick out your tongue):1 point
  • Writing: Ability to write a standard sentence (e.g., Our national bird is the peacock): 1 point
  • Attention: Count backwards from 100 by 10: 1 point

Unarousable or unable to perform IEC assessment is considered as grade 4 ICANS.

2 Evaluation-
1. MRI Brain with contrast 2. IEC scoring q6h 3. CSF panel- r/o meningoencephalitis 4. EEG 5. Repeat imaging/CSF if symptoms worsen/persist.

3 Supportive care-
1. Aspiration precautions 2. Avoid CNS depressants 3. If no seizures on EEG- use prophylactic Levetiracetam 4. Delirium

4 Seizure management-
Check Seizure protocol

5 Additional therapies-
1. Anakinra- 100mg SC daily for 7 days (Avoid if Cr Clearance <30)
2. Cyclophosphamide- 1.5g/m2 One dose (With Mesna 1.5g/m2 over 24 hours)
3. ATG- 1-2mg/kg/d for D1-3, Premed with steroid and pheniramine, Infuse over 6 hrs

4. DOSAGE FORMS AND STRENGTHS

Dosage Form: Cryopreserved viable CAR-T cells in infusion bag for single dose intravenous infusion (autologous) in 100 ml.

Composition: Each 100ml of cryopreserved cell suspension contains –
1 x 108 - 2 x 109 anti-CD19 CAR-T cells, 5% Dimethyl sulfoxide (DMSO), 6% pentastarch, 3.4% human serum albumin (HSA) and 1000 IU Heparin in Plasma-Lyte A solution q.s

Dose: ≥ 5 million CAR-T cells/ kg up to 2 x 109 viable CAR-T cells in a single infusion [see Storage and Handling (14)].

5. CONTRAINDICATIONS

None.

6. WARNINGS AND PRECAUTIONS

6.1. Cytokine Release Syndrome

CRS, including fatal or life-threatening reactions, occurred in patients following treatment with NexCAR19™. CRS occurred in 68% of patients with relapsed/refractory B-Cell Malignancies receiving NexCAR19™, including Grade 3/4 (CTCAE v.5.0 grading system) CRS in 5% [see Adverse Reactions (7)].

Key manifestations of CRS in all patients combined included fever, hypotension, tachycardia, chills, hypoxia, headache, and fatigue. Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), renal insufficiency, cardiac failure, respiratory failure, cardiac arrest, capillary leak syndrome, multi-organ failure, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (IEC-HS/MAS) [see Adverse Reactions (7)].

The median duration of hospitalization was 8 days (range: 7-21) and only 12% of the patients required ICU admission. To manage CRS a median of 1 dose (range 1-6) of tocilizumab was needed.

Ensure that at least 2 vials of tocilizumab(400mg) are available prior to infusion of NexCAR19™. Monitor patients for signs or symptoms of CRS for 4 weeks after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time [see Patient Counseling Information (15)].

At the first sign of CRS, institute treatment with supportive care or tocilizumab, or tocilizumab and corticosteroids as indicated.

6.2. Neurological Toxicities:

Neurologic toxicities, including fatal or life-threatening reactions, can occur in patients receiving NexCAR19™, including concurrently with CRS or after CRS resolution. Patients must be monitored for signs or symptoms of neurologic toxicities for 4 weeks after infusion. Provide supportive care and/or corticosteroids as needed. Patients with active neurological autoimmune or inflammatory disorder should be given NexCAR19™ at physician's discretion.

6.3. Hypersensitivity Reactions

Allergic reactions may occur with the infusion of NexCAR19™. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) in NexCAR19™.

Grading and Management of Infusion Reaction

CTCAE Version 5Grade 1Grade 2Grade 3Grade 4Grade 5
DefinitionMild transient reaction; infusion interruption not indicated; intervention not indicatedTherapy or infusion interruption indicated but responds promptly to symptomatic treatment; prophylactic medications indicated forProlonged (not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelaeLife-threatening consequences; urgent intervention indicatedDeath
ManagementContinue infusion at same rate; manage symptomsReduce infusion rate by 50%; manage symptomsInterrupt infusion. Manage symptoms, consider steroids if necessary. Rechallenge at 50% rateInterrupt infusion. Manage symptoms, consider steroids if necessary. Rechallenge at 50% rate-
6.4. Serious Infections

NexCAR19™ should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after NexCAR19™ infusion and treat appropriately. Administer prophylactic antibacterials according to local guidelines. The use of PCP prophylaxis and prophylaxis of herpes infections is recommended for up to a year post infusion. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

6.5. Cytopenia

Cytopenia was observed in all the patients receiving NexCAR19™ infusion. Monitor blood counts after NexCAR19™ infusion. Cytopenia Grade 3 or worse was observed which included neutropenia (96%), thrombocytopenia (65%), and anemia (61%), febrile neutropenia (47%).

6.6. Hypogammaglobulinemia

Hypogammaglobulinemia can occur in patients receiving treatment with NexCAR19™. Hypogammaglobulinemia was reported as an adverse reaction in 56% of all patients with relapsed/refractory B-cell Malignancies. Monitor immunoglobulin levels after treatment with NexCAR19™ and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement.

Management of Hypogammaglobulinemia –

S. NoCheckAction
1Baseline Immunoglobulin levelsPoint 2 - 4
2Serum IgG level </=400 mg/dLIVIG replacement- 0.4-0.5g/kg
3Serum IgG level 400-600 mg/dLReplace if serious/recurrent infections
4Serum IgG level >600 mg/dLEvaluate if serious/recurrent infections
5Evaluation includes-
Total IgG, IgM and IgA
CD19+ or CD20+ B-cell counts
IgG for S. pneumoniae, Tetanus and Diphtheria
If low, consider IVIG replacement or
Test antibody responses to vaccines
6Follow-up levelsAs per the protocol, at least 3-4 weekly
7Trough IgG level >400 mg/dLHold IVIG, monitor Serum IgG levels monthly for 3 months
8Trough IgG level </= 400 mg/dLContinue IVIG replacement till 3 months post infusion
Beyond that monitor levels closely and give IVIG if serious/recurrent infections
6.7. Immune effector cell–associated hematotoxicity (ICAHT)

Early ICAHT is upto 30 days; Late ICAHT >30 days. Duration and depth of neutropenia is the most critical cytopenia.

S. NoAction point
1Calculate CAR-Hematotox score
2ANC <500 for <7d → Early G-CSF in CAR-HHigh
3ANC <500 for ≥7d → Tier 1 tests
4G-CSF refractory and >D14 post infusion
Grade 3/4 → Tier 2 tests
5Consider HLH if elevated or rising ferritin
6TPO agonists in prolonged and late thrombocytopenia
G-CSF refractory cases
7Grade 3 and G-CSF refractory→Hematopoietic rescue
8Inflammatory stressor →Pulse steroids, anti-cytokine Rx
9Grade 4 for >30days → Search donor for alloSCT

Definition and grading:
Early ICAHT: ANC ≤ 500 → Grade 3(≥ 14 days) Grade 4(Never above 500).
ANC ≤ 100 → Grade 3(≥ 7 days) Grade 4(≥ 14 days )

Late ICAHT: Grade 3 → ANC ≤ 500 Grade 4 → ANC ≤ 100 (Measured on 2 occasions)

Risk of severe neutropenia >14d till Day +60.
High-risk- Optional to do Bone marrow studies and cryo-preserve PBMC &/or BM aspirate
CAR-HHigh – High CAR Hematotox score

Diagnostics:
Tier 1 tests – Nutritional (Vitamin B12, Folate), Drugs, Infections (Culture, CMV, Procalcitonin, IgG levels), Inflammation (Ferritin, Triglycerides), Marrow reserve (CBC, RPI)

Tier 2 tests- Extended viral panel (Parvo, HHV6/JC- neuro symptoms, EBV/Adeno/HSV-HLH), Bone marrow studies (MDS/AML/MF or relapse)

Tier 3- Perform BM Cytogenetics and NGS

Supportive care:
Irradiation of products- 7 days before apheresis and at least 90 days post infusion.

Antibacterial prophylaxis for CAR HHigh and mold-active antifungal prophylaxis

Reference: https://www.german-lymphoma-alliance.de/Scores.html

6.8. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

Hyperinflammatory syndrome due to IEC that manifests as CRS is resolved/resolving. Hyperferritinemia, progressive/new onset cytopenias, coagulopathy with hypofibrinogenemia and/or transaminitis.

S. NoAction point
1Check ferritin if CRS is suspected (Esp cytopenias)
2If elevated, monitor daily till it stabilizes/declines
3Check CBC, Fibrinogen, RFT, LFT, Coagulation profile daily
4Start Anakinra and titrate the doses in 48 hours1
5Use Ruxolitinib as 2nd line (Check Drug interactions)2
6Corticosteroids or Etoposide is the 3rd line option3
7Evaluate for infections
8Target Hb >7, Plt >50, Fibrinogen >150 and ANC>500
9Initiate prophylaxis4

Diagnostic criteria- Ferritin- > 2x ULN or baseline and/or rapidly rising, rising transaminases - > 5x ULN or baseline, Fibrinogen <150 mg/dL or <LLN, hemophagocytosis, Cytopenias (new onset/worsening or refractory)

Grading- 1(Asymptomatic/mild no Rx required, mild requiring Rx, moderate-severe, life-threatening)

1.Anakinra- 100-200 µg s.c/i.v q6-12 hr

2.Ruxolitinib- 10 mg BD, can increase to 20 mg BD

3.Corticosteroids- Dexa 10-40 mg daily

3.Etoposide - Low dose (50-100 mg/m2 weekly preferred)

Prophylaxis- Mold active antifungal, PJP and HSV prophylaxis

6.9. Tumor Lysis Syndrome

TLS can develop after Lymphodepleting Chemotherapy or post NexCAR19™ infusion and should be managed as per institutional guidelines. Please use appropriate TLS prophylaxis according to the individual risk of the patient.

6.10. Cerebral Edema

No episodes of Cerebral Edema were observed in the patients receiving NexCAR19™ Infusion. In case of occurrence of Cerebral Edema, following protocol can be followed for management of the same.
Initiate the protocol in case of cerebral edema, raised ICT, decerebrate/decorticate rigidity, 6th nerve palsy or Cushing's triad.

S. NoAction
1Methylprednisolone 1g/day for 3 days and taper as per the response
2Head end elevation by 30 degrees
3Mannitol- 0.5-1g/kg IV followed by 0.25-0.5g/kg q 6 hourly
Sosm <320 or Osmolal gap <40 OR
43% Saline 250ml-15min followed by 50-75 ml/hr
Target S Na <155
5Control Hypertension
MAP within 20-25 mm Hg of baseline MAP
6Metabolic profile 6 hourly
7CT Brain daily as clinically indicated Or Orbital ultrasound
8Neurosurgical consult
6.11. Effects on Ability to Drive and Use Machines

Due to the potential for neurologic events, including altered mental status or seizures, patients receiving NexCAR19™ should refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery for at least 8 weeks post infusion.

7. ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling:

  • Cytokine Release Syndrome [see Warnings and Precautions (6.1)]
  • Neurologic Toxicities [see Warnings and Precautions (6.2)]
  • Hypersensitivity Reactions [see Warnings and Precautions (6.3)]
  • Serious Infections [see Warnings and Precautions (6.4)]
  • Cytopenia [see Warnings and Precautions (6.5)]
  • Hypogammaglobulinemia [see Warnings and Precautions (6.6)]
  • Immune effector cell–associated hematotoxicity (ICAHT) [see Warnings and Precautions (6.7)]
  • Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) [see Warnings and Precautions (6.8)]
  • Tumor Lysis Syndrome [see Warnings and Precautions (6.9)]
  • Cerebral Edema [see Warnings and Precautions (6.10)]

8. CLINICAL TRIALS EXPERIENCE

The data described in the WARNINGS AND PRECAUTIONS (6) reflect exposure to a single dose of NexCAR19™ in open-label Phase I and Phase II studies conducted in patients diagnosed with relapsed or refractory B-cell Malignancies.

Refer section CLINICAL STUDIES (13) for detailed information.

9. USE IN SPECIFIC POPULATIONS

9.1. Pregnancy

Risk Summary
There are no available data with NexCAR19™ use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with NexCAR19™ to assess whether it can cause fetal harm when administered to pregnant woman. It is not known if NexCAR19™ has the potential to be transferred to the fetus. Therefore, NexCAR19™ is not recommended for women who are pregnant, and pregnancy after NexCAR19™ infusion should be discussed with the treating physician.

9.2. Lactation

Risk Summary
There is no information regarding the presence of NexCAR19™ in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NexCAR19™ and any potential adverse effects on the breastfed infant from NexCAR19™ or from the underlying maternal condition.

9.3. Females and Males of Reproductive Potential

Pregnancy Testing
Pregnancy status of females with reproductive potential should be verified. Sexually active females of reproductive potential should have a pregnancy test prior to starting treatment with NexCAR19™.

Contraception
There is no data to provide a recommendation concerning duration of contraception following treatment with NexCAR19™.

Infertility
There is no data on the effect of NexCAR19™ on fertility.

10. DESCRIPTION

NexCAR19™ is a CD19-directed genetically modified autologous T cells for Relapsed/Refractory B-cell Lymphomas and Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia. The CAR consists of a humanized single chain antibody fragment which recognizes CD19 and is fused to intracellular signaling domains from 4-1BB(CD137) and CD3 zeta through CD8 alpha hinge and transmembrane domains. The CD3 zeta component is critical for initiating T cell activation and antitumor activity while 4-1BB enhances the expansion and persistence of CAR-T. Upon binding to CD19 expressing cells, the CAR transmits a signal to promote T cell expansion, activation, target cell elimination and persistence of CAR-T.

Chimeric antigen receptor T-cell therapy (CAR-T) is a form of immunotherapy that is considered a breakthrough innovation for B-cell malignancies. In this therapy, the patients' own white blood cells (known as T-cells) are removed and modified so that they become effective in targeting and killing the cancer cells.

Qualitative and Quantitative Composition of NexCAR19™
DescriptionSpecification
General CharacteristicsMilky
ComponentsGenetically modified autologous T-cells suspension in infusion bag(s)
Product ModifiedYes
Type of Product ModificationGenetic modification of T cells by CAR encoding lentiviral vector
DosageDosage Form:
Cryopreserved viable CAR-T cells in infusion bag for single dose intravenous infusion (autologous) in 100 ml
Dose: ≥ 5 million CAR-T cells/ kg up to 2 x 109 viable CAR-T cells in a single infusion
Dosage FrequencySingle intravenous infusion
Composition of the formulationEach 100 ml of cryopreserved cell suspension contains:
1 x 108 - 2 x 109 anti-CD19 CAR-T cells
5% Dimethyl sulfoxide (DMSO),
6% pentastarch,
3.4% human serum albumin (HSA) and 1000 IU Heparin in Plasma-Lyte A Solution q.s
Packaging materialInfusion bag(s)
SterilitySterile
Shelf - LifeThe shelf life of the cryopreserved cell suspension of NexCAR19™ is 3 months from the time of manufacturing, when the infusion bag containing the product overwrapped in a sterile bag, placed in an aluminium cassette is stored at temperature ≤ -80 ºC.

11. CLINICAL PHARMACOLOGY

11.1. Mechanism of Action

NexCAR19™ involves genetic modifications of the patient's own T cells with a transgene. These CAR-T cells identify and eliminate CD19-positive malignant B cells. Since the CAR-T product identifies all the CD19-positive malignant cells, the mechanism of action of CD19 specific CAR-T cells is the same for all the disease indications.

11.2. Pharmacodynamics

NexCAR19™ is an intravenous therapy. Once NexCAR19™ is infused in the patient it starts circulating in the blood system. NexCAR19™ identifies CD19 positive B cells and upon interaction it causes activation and expansion of CAR-T cells. During these cascades of events, patients usually have symptoms like fever, nausea, mild fatigue and hypotension which is managed depending on the severity of the symptoms. CAR copies keep multiplying and killing CD19 positive B cells. Response assessment of NexCAR19™, its expansion and persistence in the circulatory system is measured by PCR and/or flow cytometry.

11.3. Pharmacokinetics

NexCAR19™ pharmacokinetics was studied in Phase I and Phase II clinical trial. NexCAR19™ was seen to undergo four phase dynamics – distribution, expansion, contraction, and persistence. The distribution phase lasts up to 07 days post infusion, followed by logarithmic expansion phase to achieve peak expansion by 14-21 days. Post peak expansion, NexCAR19™ levels contract by day 28 and continue to persist as per the disease remission state, patient physiological and other factors. NexCAR19™ cells have been shown to persist beyond 12 months in the patients post infusion, as evaluated by qPCR.

12. NONCLINICAL TOXICOLOGY

12.1. Pharmacology

NexCAR19™ constitutes autologous T-cells that are genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor. To determine functional efficacy, the NexCAR19™ cells were administered into immunodeficient NOD/SCID mice bearing CD19+ Nalm-6 (acute lymphoblastic leukemia) and tumor burden was monitored. A significant reduction in tumor was observed after NexCAR19™ treatment. These specific pharmacological actions demonstrate the therapeutic potential of the product for humans. The detailed characterization study has been presented in Dwivedi, Alka, et al. article on "Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells." Molecular Cancer Therapeutics 20.5 (2021): 846-858.

12.2. Toxicology

NexCAR19™ comprises engineered human T-cells, therefore there are no representative in vitro assays, ex vivo models, or in vivo models that can accurately address the toxicological characteristics of the human product. However, single, and multiple dose toxicological characteristics for NexCAR19™ were performed in NOD/SCID mice. The safety profile was evaluated by serum hematological parameters such as hemoglobin levels, RBC count, WBC count, platelets count etc.; serum biochemistry parameters such as AST/SGOT levels, ALT/SGPT levels, Total protein etc. and Histopathology of vital organs - heart, lungs, liver, kidney, spleen, lymph nodes and bone marrow. Additionally, in vivo safety evaluation for off-target toxicities did not show any systemic toxicity and tumorigenicity. The detailed characterization study has been presented in Dwivedi, Alka, et al. article on "Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells." Molecular Cancer Therapeutics 20.5 (2021): 846-858.

13. CLINICAL STUDIES

The data described in the WARNINGS AND PRECAUTIONS (6) reflect exposure to a single dose of NexCAR19™ in Open-Label Phase I and Phase II studies with 64 patients diagnosed with relapsed or refractory B-cell Malignancies.

Relapsed or Refractory B-cell Malignancies
A total of 64 patients with r/r B-cell lymphoma (n=47), r/r B – Acute Lymphoblastic Leukemia(B-ALL) (n=17) were enrolled in two Phases (Phase I; 11/05/2021 till 13/05/2022 and Phase II; 27/12/2022 till 31/08/2023), 62 out of 64 underwent leukapheresis and 57 received NexCAR19™ in Phase 1 (n=10) and Phase II (n = 47). 51 patients (Phase I (n= 5), Phase II (n = 46)) were part of the efficacy evaluable cohort having received a dose ≥ 5 x 106 cells/kg and a lymphodepleting therapy consisting of cyclophosphamide and fludarabine over three days prior to CAR-T cell therapy. The median age was 44 years (IQR 27-57) with 49 (77%) male patients. The median prior lines of therapy were 2 (IQR 1-3). The median vein-to-vein time was 14 (IQR 14-26) days. The overall response rate in patients with r/r B-cell lymphoma was 72% and the complete response rate was 53%. The overall response rate in patients with r/r B-ALL was 73%.
CRS developed in 68% cases. Grade 3 or worse CRS occurred in none of the 42 patients with B-cell lymphoma and 3(20%) of 15 patients with B-ALL. None of the patients developed ICANS of any grade with a single infusion of NexCAR19™. The most common adverse events were fever (77%) and fatigue (46%). The most common grade 3 or worse toxicities were hematological events; anemia, thrombocytopenia, neutropenia and febrile neutropenia occurred in 61% ,65% 96% and 47% respectively. The median duration of hospitalization was 8 days (range: 7-21) and only (12%) of the patients required ICU admission. To manage CRS a median of 1 dose (range 1-6) of tocilizumab was needed. 17% of patients required dexamethasone. Only 3 of the 15 leukemia patients required vasopressor support. Intravenous Immunoglobulins were administered to 51% of the patients to manage hypogammaglobulinemia.

Table 3: Summarizes list of adverse reactions in patients treated with NexCAR19™ in Phase I and Phase II trial

Toxicities, n (%)All patients (n=57)B-cell lymphoma (n=42)B-ALL (n=15)
Cytokine Release Syndrome
Grade 3/43 (5)0 (0)3 (20)
All grades39 (68)26 (62)13 (87)
ICANS
Grade 3/40 (0)0 (0)0 (0)
All grades0 (0)0 (0)0 (0)
Hypogammaglobulinemia*
All grades32 (56)24 (57)8 (53)
IEC-HS**
All grades7 (12)6 (14)1 (7)
Hematological Toxicities
Anemia
Grade 3/435 (61)24 (57)11 (73)
All grades55 (96)40 (95)15 (100)
Platelet Count Decreased
Grade 3/437 (65)25 (60)12 (80)
All grades51 (89)36 (86)15 (100)
Neutrophil Count Decreased
Grade 3/455 (96)40 (95)15 (100)
All grades56 (98)41 (98)15 (100)
Febrile Neutropenia
Grade 3/427 (47)17 (40)10 (67)
All grades27 (47)17 (40)10 (67)

14. STORAGE AND HANDLING

14.1. Storage:

Storage conditions: ≤ -80 degree Celsius

14.2. Special precautions for handling:
  • Confirm patient's identity upon receipt of the product. Confirm Patient ID prior to infusion and verify Patient ID in a conspicuous manner.
  • The expiry date is indicated on the product label. The shelf life of the product is 3 months.
  • Do not thaw the product until it is ready to be used. NexCAR19™ must be kept out of the reach and sight of children.
  • Use closed, leak-proof, break-proof containers while transporting infusion bag(s) within the facility.
  • Aseptic Conditions: Proper Aseptic conditions should be followed while thawing and handling the product.
  • Once thawed, do not refreeze.
14.3. Special Precautions for disposal:
  • Any unused product or waste material should be disposed of in accordance with biomedical waste management guidelines of the healthcare centre.
  • NexCAR19™ products should be transported within the facility in closed, break-proof, leak-proof containers.
14.4. Solid and liquid waste:

All material having been in contact with NexCAR19™ should be handled and disposed of as potentially infectious waste in accordance with local hospital procedures.

15. PATIENT COUNSELING INFORMATION

Advise the patient to read CDSCO approved Medication guide to know more about the NexCAR19™ (Appendix A: Medication Guide)

  1. Ensure that the patient understands the risk of manufacturing failure.
  2. Advise the patient to avoid intake of any steroids and chemotherapy treatment at least 24 hours prior to apheresis procedure and NexCAR19™ infusion.
  3. Advise patients to immediately report signs and symptoms like fever, nausea, diarrhea, dizziness, fatigue, lethargy, difficulty concentrating, agitation, tremor; and consult his/her treating physician for the management of the same.
  4. Female patients should inform their treating physician in advance if they are pregnant or planning a pregnancy or they are lactating. It is advised not to use the medication during pregnancy or lactating.
  5. Advise patients not to take other medication without consulting with the treating physician.
  6. Patients are instructed to receive irradiated blood products if at all indicated for use, post NexCAR19™ infusion.

16. APPENDIX A: Medication Guide

MEDICATION GUIDE

NexCAR19™ (Talicabtagene autoleucel)

(Genetically modified Autologous T cells for intravenous infusion)

Read this Medication Guide before you start your NexCAR19™ treatment. The more you know about your treatment, the more active you can be in your care. Talk with your treating physician if you have questions about your health condition or treatment. Reading this Medication Guide does not take the place of talking with your treating physician about your treatment.

What is the most important information I should know about NexCAR19™?

NexCAR19™ may cause side effects that are severe or life-threatening. Call your treating physician or get emergency help right away if you get any of the following:

  • Difficulty breathing
  • Fever (100.4°F/38°C or higher)
  • Chills/shaking chills
  • Confusion
  • Severe nausea, vomiting, diarrhea
  • Severe muscle or joint pain
  • Difficulty concentrating
  • Dizziness
  • Fatigue

It is important that you tell your treating physicians that you have received NexCAR19™. The treating physicians may give you other medicines to treat your side effects.

NexCAR19™ is not recommended for pregnant and lactating women. Pregnancy after NexCAR19™ infusion must be discussed with the treating physician.

What is NexCAR19?

NexCAR19™ is a genetically modified autologous product, a form of immunotherapy that is considered a breakthrough innovation for B-cell malignancies. In this therapy, the patients' own white blood cells (known as T-cells) are collected and modified in the laboratory so that they become effective in targeting and killing the cancer cells.

How will I get NexCAR19™?

Since NexCAR19™ is made from your own white blood cells, your treating physician has to take some of your blood. This is called “leukapheresis.” It can take up to 3 to 4 hours and may need to be repeated. Blood for leukapheresis will be collected through peripheral vein or by using the central line.

Your blood cells are sent to the manufacturing site to make NexCAR19™. It takes about 2-3 weeks from the time your cells are received at the manufacturing site and shipped back to your treating physician, but the time may vary.

While waiting for NexCAR19™ to be made, your treating physician may give you therapy to stabilize your cancer. In addition, before you get NexCAR19™, your treating physician may give you chemotherapy for a few days to prepare your body. Your physician will examine you for the suitability of NexCAR19™ infusion.

The infusion takes less than one hour. You should plan to stay within 2 hours from the hospital after receiving the NexCAR19™ for at least 4 weeks.

What should I avoid after receiving NexCAR19™?
  • Do not drive, operate heavy machinery, or participate in any adventure activity or sports for approximately 8 weeks after you get NexCAR19™ because the treatment can cause temporary memory and coordination problems, including sleepiness, confusion, weakness, dizziness, and seizures.
  • Do not donate blood, organs, tissues, sperm, oocytes, and other cells without consulting your treating physician.
What are the possible or reasonably likely side effects of NexCAR19™?

The most common side effects of NexCAR19™ are:

  • Fever (100.4°F/38°C or higher)
  • Difficulty breathing
  • Very low blood pressure
  • chills/shaking chills
  • confusion
  • Nausea, vomiting, diarrhea
  • Muscle or joint pain
  • Dizziness
  • Headache

Tell your treating physician right away if you develop fever, chills, or any signs or symptoms of an infection. Call your doctor for medical advice about any side effects.

General information about the safe and effective use of NexCAR19™
  • Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
  • Do not use NexCAR19™ for a condition for which it was not prescribed. Talk to your treating physician about any concerns.

Manufactured and Distributed by: Immunoadoptive Cell Therapy Private Limited (ImmunoACT)

Registered Office: Plot No. D-222/26, TTC Industrial Area, MIDC, Village Shiravane, Navi Mumbai-400706

Corporate Office and Laboratory: 1st Floor, Plot No. R-977, TTC Industrial Area, MIDC, Rabale, Navi Mumbai - 400701

In case of any SUSAR (Suspected Unexpected Serious Adverse Reaction), kindly inform on:
Contact: pharmacovigilance@immunoact.com

This section is strictly intended for access by qualified Healthcare Professionals (HCPs) only. The information provided herein contains scientific, educational material related to pharmaceutical products/devices, and therapeutic interventions. 
 
By selecting ‘I am an HCP,’ you confirm and declare that you are a licensed healthcare professional who is legally permitted to review such information under applicable laws, professional regulations, and ethical guidelines. 
If you are not an HCP, you are hereby advised to refrain from accessing this content, as it is not intended for the general public or for nonmedical audiences